Targeting EZH2 and PRC2 dependence as novel anticancer therapy.
about
Polycomb repressive complex 2 structure with inhibitor reveals a mechanism of activation and drug resistance.Significance of EZH2 expression in canine mammary tumors.Recurrent EZH1 mutations are a second hit in autonomous thyroid adenomasThe roles of AKR1C1 and AKR1C2 in ethyl-3,4-dihydroxybenzoate induced esophageal squamous cell carcinoma cell deathUnique epigenetic gene profiles define human breast cancers with poor prognosis.Inhibitors of the Histone Methyltransferases EZH2/1 Induce a Potent Antiviral State and Suppress Infection by Diverse Viral Pathogens.Loss of RUNX3 expression is an independent adverse prognostic factor in diffuse large B-cell lymphoma.Mutations in epigenetic modifiers in acute myeloid leukemia and their clinical utility.Targeting epigenetic regulators for cancer therapy: modulation of bromodomain proteins, methyltransferases, demethylases, and microRNAs.Diagnostic and Therapeutic Implications of Histone Epigenetic Modulators in Breast Cancer.TUG1: a pivotal oncogenic long non-coding RNA of human cancers.A chemical probe toolbox for dissecting the cancer epigenome.Structure of the PRC2 complex and application to drug discovery.Orchestration of H3K27 methylation: mechanisms and therapeutic implication.Current advances of long non-coding RNA highly upregulated in liver cancer in human tumors.Gene enhancer deregulation and epigenetic vulnerability.The histone methyltransferase EZH2 as a druggable target in SHH medulloblastoma cancer stem cells.Pharmacologic Targeting of Chromatin Modulators As Therapeutics of Acute Myeloid LeukemiaThe Role of the Histone Methyltransferase Enhancer of Zeste Homolog 2 (EZH2) in the Pathobiological Mechanisms Underlying Inflammatory Bowel Disease (IBD).EZH2 promotes hepatocellular carcinoma progression through modulating miR-22/galectin-9 axis.Pyrazole-based inhibitors of enhancer of zeste homologue 2 induce apoptosis and autophagy in cancer cells.Melatonin inhibits tumorigenicity of glioblastoma stem-like cells via the AKT-EZH2-STAT3 signaling axis.Cancer Is to Embryology as Mutation Is to Genetics: Hypothesis of the Cancer as Embryological Phenomenon.
P2860
Q27319398-D77CB0DC-F15D-4244-909C-03937F3556BAQ36098022-3EE6106A-C3E6-4FE7-A8EB-48EA3EE653E4Q37217469-4BA1A588-9BCD-471E-95A7-8B95FB648187Q37225331-65C528CC-6F1B-4B57-9521-F3F8FF5D49BFQ37699138-307E9E9F-659E-4BCA-B151-B254DE13B63EQ38156730-164A3F18-FCD2-4E23-882B-5F3017C0821BQ38380322-E3B7ECB9-CBFC-48C5-A68D-90B58A05DB9EQ38703904-1AE9CF3E-C872-490E-9FEB-56F60920F291Q38707876-FE278EF7-CFCE-407D-BB80-0EC8E1D29D69Q38741165-59CA7D89-3B0F-4324-905F-13E8FC717182Q38875365-9A54DDA3-0247-4355-A69C-90608583D754Q39147132-CCDDE31F-BD37-47B4-AE24-096B89DC0F16Q39245946-F0209367-33BB-4428-BAE4-C8A9ADA787ACQ39440781-DDC263A4-C0BA-41E7-97EA-B90ECF91705FQ42283216-034CF7D8-69A2-4DF2-801B-3A419F284197Q42330450-9849A89D-C628-4082-9355-0B8C5EF77662Q42366629-96D67982-25A6-4C5C-BBEE-9C31C1C10249Q42694670-4337296E-1123-429A-9483-624A6D4A4338Q46382588-4907FDC3-1D7A-4FC9-AD4F-2FD6CD6B60DDQ50115221-50A3AA0F-37F0-4313-AB36-3D327318547FQ52568730-4AA245F6-68C3-4CDA-A302-EFAB1CAA9E38Q53113443-2F1A558A-6F1A-4E42-BFEA-53AC1FB7DBE3Q54946976-714BB0C9-1F00-47C6-AEB5-8B69B5FF3061
P2860
Targeting EZH2 and PRC2 dependence as novel anticancer therapy.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh
2015年學術文章
@zh-hant
name
Targeting EZH2 and PRC2 dependence as novel anticancer therapy.
@ast
Targeting EZH2 and PRC2 dependence as novel anticancer therapy.
@en
type
label
Targeting EZH2 and PRC2 dependence as novel anticancer therapy.
@ast
Targeting EZH2 and PRC2 dependence as novel anticancer therapy.
@en
prefLabel
Targeting EZH2 and PRC2 dependence as novel anticancer therapy.
@ast
Targeting EZH2 and PRC2 dependence as novel anticancer therapy.
@en
P2093
P2860
P1476
Targeting EZH2 and PRC2 dependence as novel anticancer therapy.
@en
P2093
Gang Greg Wang
Kyle D Konze
P2860
P304
P356
10.1016/J.EXPHEM.2015.05.001
P577
2015-05-28T00:00:00Z